Benzinga | Sep 22, 2021 07:59AM EDT

Mizuho Maintains Buy on bluebird bio, Lowers Price Target to $23

Mizuho analyst Difei Yang maintains bluebird bio (NASDAQ:BLUE) with a Buy and lowers the price target from $29 to $23.